Semaglutide and tirzepatide are the two most-prescribed medications in modern medical weight loss, and they are often discussed as if they were interchangeable. They are not. They differ in how they work, what the clinical trials showed, how the body tends to tolerate them, and how providers think about matching them to an individual patient. This guide walks through those differences in plain language, so the conversation with your provider starts from an informed place.
The short answer
If you want the one-paragraph version: tirzepatide produced larger average weight loss in its pivotal trial (20.9% of body weight at the highest dose in SURMOUNT-1) than semaglutide did in its own pivotal trial (14.9% in STEP 1). But trial averages are not a prescription. Semaglutide has a longer track record, both medications share a similar side-effect profile, and individual response varies widely — some patients lose more on semaglutide than the tirzepatide average, and vice versa.
The medication that is "right for you" is the one a licensed provider selects after reviewing your health history, your goals, your tolerance for side effects, and your budget. Everything below explains the factors that go into that decision.
How semaglutide works
Semaglutide is a GLP-1 receptor agonist. GLP-1 (glucagon-like peptide-1) is a hormone your gut releases naturally after you eat. It tells your brain you are full, slows how quickly food leaves your stomach, and helps your pancreas release insulin when blood sugar rises.
The natural hormone breaks down within minutes. Semaglutide is engineered to resist that breakdown, so a single weekly injection keeps the signal active continuously. The practical effect most patients describe: appetite quiets down, portions shrink without white-knuckle willpower, and the constant background noise of food cravings — what many patients call "food chatter" — fades.
Semaglutide was approved by the FDA for chronic weight management in 2021 under the brand name Wegovy, after years of use at lower doses for type 2 diabetes (Ozempic).
How tirzepatide works
Tirzepatide does everything semaglutide does, plus one more thing: it also activates the GIP receptor (glucose-dependent insulinotropic polypeptide). GIP is a second incretin hormone involved in how the body processes fat and regulates insulin.
Researchers believe this dual-agonist design is why tirzepatide trials showed larger average weight reduction — the two pathways appear to reinforce each other. Tirzepatide was FDA-approved for chronic weight management in late 2023 under the brand name Zepbound, following its diabetes approval as Mounjaro.
For patients, the day-to-day experience is similar to semaglutide: a once-weekly injection, reduced appetite, earlier fullness. Some patients who plateau on semaglutide respond when switched to tirzepatide, which is one reason providers value having both options.
What the head-line trials actually showed
In STEP 1 (New England Journal of Medicine, 2021), adults without diabetes taking semaglutide 2.4mg weekly lost an average of 14.9% of body weight over 68 weeks, versus 2.4% with placebo. For a 220-pound person, that average works out to roughly 33 pounds.
In SURMOUNT-1 (NEJM, 2022), adults taking tirzepatide 15mg weekly lost an average of 20.9% over 72 weeks, versus 3.1% with placebo. Same 220-pound person: roughly 46 pounds at the trial average.
Two important caveats. First, these are different trials with different participants — not a direct head-to-head. The first true head-to-head trial, SURMOUNT-5, reported tirzepatide ahead, but individual variation remained large in both arms. Second, both trials included lifestyle support. The medications work best as part of a complete plan, not as a substitute for one.
Side effects: more alike than different
Both medications share the same core side-effect profile, because both slow digestion. The most common effects are nausea, constipation, diarrhea, and reflux — typically worst in the first weeks after starting or increasing a dose, and typically improving as the body adapts.
In the trials, gastrointestinal side effects led a small percentage of participants to discontinue (about 7% for semaglutide in STEP 1; about 4–7% across tirzepatide doses in SURMOUNT-1). Most patients manage symptoms with smaller meals, slower eating, hydration, and a conservative titration schedule.
Both medications carry the same serious-but-rare warnings: pancreatitis, gallbladder disease, and a thyroid C-cell tumor warning from rodent studies, which is why a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome rules both medications out. Neither is used during pregnancy.
Cost and access
Brand-name GLP-1 medications retail for roughly $1,000–$1,400 per month without insurance, and coverage for weight management (as opposed to diabetes) remains inconsistent.
Compounded versions of semaglutide and tirzepatide, prepared by licensed compounding pharmacies, are typically a fraction of that price — which is what makes programs starting around $179–$349/month possible. One thing we are required to be clear about, and want to be clear about: compounded medications are not FDA-approved products. They contain the same active pharmaceutical ingredient but are not individually reviewed by the FDA. A licensed provider determines whether a compounded option is appropriate for you.
Tirzepatide is generally more expensive than semaglutide in both brand and compounded forms, which is a legitimate factor in the decision for many patients.
How a provider actually decides
When a licensed provider reviews your intake, they are weighing several questions. How much weight is clinically appropriate to target? A patient with a BMI of 32 and no metabolic disease may not need the strongest available option. What is the medication history — has the patient tried a GLP-1 before, and how was it tolerated? Are there contraindications: pancreatitis history, gallbladder disease, thyroid cancer history, pregnancy plans?
Budget matters too, and a good provider treats it as a clinical factor rather than an afterthought — the best medication is one you can actually stay on for the months it takes to reach and maintain your goal.
A common pattern: start with semaglutide for its longer track record and lower cost, escalate to tirzepatide if results plateau or if the patient has a larger amount of weight to lose. But patterns are not rules, and your provider may reason differently based on your specific profile.
Frequently asked questions
Can I switch between them? Yes — switching is common and is managed by your provider, usually with an adjusted starting dose rather than jumping to the equivalent top dose.
Is tirzepatide always better because the trial number is higher? No. Trial averages compare populations, not people. Tolerability, cost, and your individual response matter more than a four-point difference in trial averages.
How fast will I see results? Most patients notice appetite changes within the first one to two weeks, and measurable weight change within the first month. The trial results above took 68–72 weeks — this is a months-long process by design.
Do I qualify? Eligibility generally starts at BMI ≥ 30, or ≥ 27 with a weight-related condition such as hypertension or prediabetes — but only a licensed provider can determine whether treatment is appropriate for you, which is exactly what the online assessment is for.